Suggestions

EHC · NYSE

ENCOMPASS HEALTH CORP

Private beta

Sector unavailable · Industry unavailable

$121.71

+0.55%

Close on Sep 11, 2026

Insufficient Data

Updated 12/19/2023

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Investment Report Card

ENCOMPASS HEALTH CORP

Sector unavailable · Data confidence partial

46 / 100

Rank #406 of 1,152 qualified companies

Top 59% · Not Currently Suggested

Risk Intelligence

Core Model
C

65 / 100

Insufficient Data

How strong and defensively sound is the company?

Around the middle of the covered universe.

Long-Term Potential

Research Model
D+

52 / 100

Insufficient Data

Does the business have the characteristics needed to create value over many years?

Weaker than most covered companies on this measure.

Fundamental Momentum

Research Model
F

32 / 100

Insufficient Data

Is the underlying business getting stronger or weaker?

Weaker than most covered companies on this measure.

Ownership Intelligence

Supplemental Intelligence
A

90 / 100

Positive disclosed activity

What are important owners actually doing?

Among the strongest readings on this measure.

Valuation Intelligence

Research Model
F

40 / 100

Elevated

Is today's price reasonable?

Weaker than most covered companies on this measure — and valuation is researched separately from the Suggested Investment Score.

Capital Returns Intelligence

Research Model
D

49 / 100

Moderate Capital Returns

How effectively does the company reward shareholders?

Weaker than most covered companies on this measure — and capital returns are researched separately from the Suggested Investment Score.

Why it stands out

  • More disclosed holders are new or increasing than reducing or exiting.

What holds it back

  • Elevated valuation: the current market price reflects a premium to this company's historical valuation and comparable companies (Valuation Intelligence 40 out of 100, Elevated).

Long-term view

ENCOMPASS HEALTH CORP scores 52 on Long-Term Potential (D+), described by the research model as insufficient data. This describes business characteristics only — it is not a forecast of future returns.

Ownership view

Disclosed ownership evidence reads 90 (A): Positive disclosed activity. 2 tracked managers disclosed a position in the latest reporting period. Ownership filings are historical disclosures, not signals.

Valuation view

ENCOMPASS HEALTH CORP reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

Capital returns view

ENCOMPASS HEALTH CORP reads 49 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

What changed

No meaningful recorded changes in the stored history.

Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.

Compare EHC with other companies

Research Collections

This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.

Browse collections

About a minute to read

The 60-Second Investment Brief

Written from stored research readings only. No hype. No trading signals. Just better evidence.

Why it's interesting

ENCOMPASS HEALTH CORP (EHC) scores 46 out of 100 and ranks #406 of 1,152 qualified companies today. That places it in the top 59% of ranked companies. The stored tier for that score is not currently suggested.

Business strength

Risk Intelligence reads 65 out of 100 (C), recorded as insufficient data. Around the middle of the covered universe.

Long-term opportunity

Long-Term Potential reads 52 out of 100 (D+), recorded as insufficient data. Weaker than most covered companies on this measure.

What's improving or weakening

Fundamental Momentum reads 32 out of 100 (F), recorded as insufficient data. Weaker than most covered companies on this measure.

What important owners are doing

Ownership Intelligence reads 90 out of 100 (A), recorded as positive disclosed activity. Among the strongest readings on this measure.

What kind of price you'd be paying

Valuation is currently the main point of caution: Valuation Intelligence reads 40 out of 100 (F), recorded as Elevated. ENCOMPASS HEALTH CORP reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

How the company rewards shareholders

Capital Returns Intelligence reads 49 out of 100 (D), recorded as Moderate Capital Returns. ENCOMPASS HEALTH CORP reads 49 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

What could go wrong

Elevated valuation: the current market price reflects a premium to this company's historical valuation and comparable companies (Valuation Intelligence 40 out of 100, Elevated). Data confidence for this company is partial.

Bottom line

Its strongest recorded evidence is Ownership Intelligence. Long-Term Potential and Fundamental Momentum remain the main area to watch. Separately from the score, valuation reads elevated at today's price.

Composite discovery model

Suggested Investment Score

Suggested Investment Score

46 / 100

Not Currently Suggested

A 0–100 composite discovery score combining Risk Intelligence, Long-Term Potential, Fundamental Momentum, and Ownership Intelligence. It helps rank qualified companies for further research and does not predict future returns.

Rank
#406 of 694
Percentile
Top 59%
Ranking updated
September 12, 2026
Rank unchanged. Rank unchanged.
Risk Intelligence
65

30% contribution

Long-Term Potential
52

30% contribution

Fundamental Momentum
32

20% contribution

Ownership Intelligence
90

20% contribution

Ownership Intelligence

90 / 100 · Strong · 20% of the Suggested Investment Score

SUPPLEMENTAL / DESCRIPTIVE INTELLIGENCE

Coverage: Partial Coverage

Elite Investor Activity
Insufficient Data

50% of Ownership Intelligence · 10% of the total score

No reliably mapped professional-manager filings are stored, so this evidence is unavailable rather than neutral.

Institutional Activity
90 · Strong

20% of Ownership Intelligence · 4% of the total score

Broad institutional evidence from resolved filings is strong.

Insider Activity
Insufficient Data

15% of Ownership Intelligence · 3% of the total score

No discretionary insider transactions are stored for this company, so this evidence is unavailable rather than neutral.

Strategic Ownership
Insufficient Data

15% of Ownership Intelligence · 3% of the total score

No qualifying major-holder filings are stored, so this evidence is unavailable rather than neutral.

Ownership Intelligence summarizes publicly disclosed activity among professional investment managers, broader institutions, company insiders, and significant strategic owners. It adds context to investment research but is not a validated predictor of future performance. Ownership information is publicly reported with a delay; the latest applicable reporting period is 2026-06-30, publicly disclosed 9/11/2026. Congressional activity is unavailable pending legal review and contributes nothing to this reading.

Why it ranks here

No component ranks in the top quartile of the qualified universe.

What holds it back

  • Long-term potential is mid-pack

    Long-Term Potential ranks below the qualified median. This remains a research model.

  • Fundamental Momentum is softer

    Reported business trends rank below the qualified median.

  • Ownership Intelligence — Partial Coverage

    Only part of the ownership evidence is available for this company. Missing evidence is left missing rather than replaced with a neutral value.

COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Data coverage Good. Rankings are recalculated daily using the latest available information. Individual components may update at different frequencies based on when new financial and ownership data becomes available.

Researched separately

Valuation Intelligence 40 · Elevated

RESEARCH MODEL

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

Researched separately

Capital Returns Intelligence 49 · Moderate Capital Returns

RESEARCH MODEL

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

Score explanation

Why this company scores the way it does

Four research areas carry fixed weights. Each area is compared against every other eligible company, then weighted. The four contributions below add to 45.7 of the stored score (45.7).

  • Risk Intelligence

    30% of the score · contributes 15.2 points

    How strong and defensively sound is the company?

    Stands at the 51 percentile of eligible companies · stored reading 65 · 33% of this company’s total score

    How financially sturdy the company has been when conditions turned against it.

    How this area is measured

    Risk Intelligence reads stored balance-sheet strength, historical downside behaviour and the company's price-risk grouping. A stronger reading describes past resilience; it does not protect against future losses.

    Full methodology
  • Long-Term Potential

    30% of the score · contributes 12.7 points

    Does the business have the characteristics needed to create value over many years?

    Stands at the 42 percentile of eligible companies · stored reading 52 · 28% of this company’s total score

    Whether the business has the durable characteristics long-term owners look for.

    How this area is measured

    Long-Term Potential reads durability characteristics such as profitability consistency, cash generation and reinvestment capability over multiple reported periods.

    Full methodology
  • Fundamental Momentum

    20% of the score · contributes 3.0 points

    Is the underlying business getting stronger or weaker?

    Stands at the 15 percentile of eligible companies · stored reading 32 · 7% of this company’s total score

    Whether the reported business results have been getting stronger or weaker.

    How this area is measured

    Fundamental Momentum compares recent reported fundamentals with the company's own earlier periods, so improvement or deterioration is measured against its history rather than against a forecast.

    Full methodology
  • Ownership Intelligence

    20% of the score · contributes 14.8 points

    What are important owners actually doing?

    Stands at the 74 percentile of eligible companies · stored reading 90 · 32% of this company’s total score

    What large reporting owners have actually been doing with their positions.

    How this area is measured

    Ownership Intelligence reads public ownership filings: how many tracked reporting owners hold the company, and whether they were adding, holding, reducing or exiting in the latest disclosed period.

    Full methodology

What is helping the score

  • Ownership Intelligence74 percentile, adding 14.8 points.

What deserves attention

  • Fundamental Momentum15 percentile, adding only 3.0 of a possible 20 points.
  • Long-Term Potential42 percentile, adding only 12.7 of a possible 30 points.
Outside the score

Additional research — not currently included in the primary Suggested Investment Score.

  • Valuation IntelligenceENCOMPASS HEALTH CORP reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
  • Capital Returns IntelligenceENCOMPASS HEALTH CORP reads 49 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years.

Stored snapshots only

What changed

Research-score history available since September 2026.

Stored research history does not yet cover a full 30 days comparison for this company.

A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

Fifth research lens · outside the score

Valuation Intelligence

Valuation Intelligence

Is today's price reasonable?

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

40/ 100

Elevated

RESEARCH MODEL
Excellent coverage

Compared with its history

28

Expensive

Is this company expensive or inexpensive compared with its own history?

Compared with peers

35

Elevated

How expensive is this stock compared with similar companies?

Earnings & cash flow

59

Reasonable

How much financial output does an investor receive relative to the price paid?

Growth-adjusted

40

Elevated

Does the company's growth help justify the valuation investors are paying?

ENCOMPASS HEALTH CORP reads 40 out of 100 on Valuation Intelligence, recorded as Elevated. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Valuation history

Stored readings only. The dashed line is this company's own median for the selected measure.

Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.

Current P/E 19.3x · own median 17.4x · peer median 18.3x

Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.

Sixth research lens · outside the score

Capital Returns Intelligence

Capital Returns Intelligence

How effectively does the company reward shareholders?

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

49/ 100

Moderate Capital Returns

RESEARCH MODEL
Excellent coverage

Dividend Quality

53

Moderate Capital Returns

Dividend reliability

Buyback Effectiveness

42

Moderate Capital Returns

Do buybacks actually reduce shares?

The company spends on share repurchases, but much of that activity offsets share issuance rather than materially reducing the share count.

Dilution Control

43

Moderate Capital Returns

Is your ownership share protected?

Capital Return Sustainability

62

Favorable Capital Returns

Can the cash flow support it?

Shareholder Yield

40

Limited Capital Returns

Cash returned versus company value

ENCOMPASS HEALTH CORP reads 49 out of 100 on Capital Returns Intelligence (Moderate Capital Returns), reflecting a dividend paid for 13 consecutive years.

This company spent cash repurchasing stock, but the share count did not fall meaningfully because it also issued shares. Repurchase spending alone did not increase existing shareholders' ownership.

How returned cash was used

Dividends $75.20M · net repurchases $247.00M · total returned $322.20M · 78% of free cash flow

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Capital returns history

Stored readings only. History builds forward from activation rather than being reconstructed.

Only one stored reading exists for this measure so far, so there is nothing to chart yet.

Why higher yield isn't always better

A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.

Why buybacks can be misleading

Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.

What these terms mean
Dividend Yield
The annual dividend relative to the current share price.
Payout Ratio
The share of company earnings used to pay dividends.
Free Cash Flow Payout
How much of the company's available cash is being used for dividends.
Share Repurchases
When a company buys back its own stock.
Dilution
When the number of shares increases, reducing each existing share's percentage ownership of the company.
Shareholder Yield
A combined view of dividends and net share repurchases relative to the company's market value.

Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Suggested Investment Score.

Stored daily snapshots only

Ranking history

Stored Suggested Investment ranking history
Today#406Score 46
30 days agoNot rankedNo stored score
90 days agoNot rankedNo stored score
First suggestedNot yet suggested
Highest rank#406

In the company’s own words

What this company does

We are the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment, using advanced technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence and quality of life. We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of December 31, 2025, we operated 173 inpatient rehabilitation hospitals. We are committed to delivering high-quality, cost-effective patient care. For 2025, we were named America’s Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and ranked among Fortune’s World’s Most Admired Companies and Forbes’ Most Trusted Companies in America.

Our common stock is traded on the New York Stock Exchange (symbol "EHC"). Our principal executive offices are located at 9001 Liberty Parkway, Birmingham, Alabama 35242, and the telephone number of the principal executive offices is (205) 967-7116. Our website address is www.encompasshealth.com.

In addition to the discussion here, we encourage the reader to review Item 1A, Risk Factors , Item 2, Properties, and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations , which highlight additional considerations about our Company.

Our inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive, high-quality, cost-effective patient care services. As participants in the Medicare program, our hospitals must be licensed and certified and otherwise comply with various requirements that are discussed below in the "Sources of Revenues—Medicare Reimbursement" section. Substantially all (92%) of the patients we serve are admitted from acute-care hospitals following physician referrals for specific acute inpatient rehabilitative care. Most of those patients have experienced significant physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and a variety of debilitating neurological conditions, that are generally nondiscretionary in nature and require rehabilitative healthcare services in a facility-based setting. Our teams of highly skilled nurses and physical, occupational, and speech therapists utilize proven technology and clinical protocols with the objective of restoring our patients’ physical and cognitive abilities. Patient care is provided by nursing and therapy staff as directed by physician orders while case managers and other clinical staff monitor each patient’s progress and provide documentation and oversight of patient status, achievement of goals, discharge planning, and functional outcomes. Our hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages innovative technologies and advanced therapies and achieves superior outcomes.

Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing

Four distinct intelligence areas

The IA view

Risk Intelligence

Production core

65

Fundamentally Qualified

No prior period to compare

Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.

As of Sep 11, 2026

Long-Term Potential

Research model

52

Ordinary Compounder

No prior period to compare

Durable business economics and reinvestment characteristics. Independent external validation is pending.

As of Sep 11, 2026

Fundamental Momentum

Research model

32

Deteriorating

No prior period to compare

Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.

As of Sep 11, 2026

Elite Investor Activity

Supplemental

Insufficient Data

No prior period to compare

Too few tracked managers disclosed a position to describe consensus.

Intelligence history

Not enough stored history to chart EHC yet. A company needs at least two published research or ownership periods before a trend can be shown.

Share price

EHC price history

Closing prices adjusted for splits and dividends, through Sep 11, 2026. Past prices do not indicate future results.

6M change
+21.8%
1Y change
-3.3%
3Y change
+81.4%
5Y change
+107.1%
Max change
+134.3%

Last stored close $121.71 · -3.3% over the selected range · 52 sessions shown

Balanced evidence

Why IA likes it

  • More disclosed holders are new or increasing than reducing or exiting.

Risk and uncertainty

What IA doesn’t like

  • No specific negative evidence is available. This is not evidence of low risk.

What would change our view

  • Business Quality falling below the frozen qualification threshold.
  • Price Risk moving to a less favorable category.
  • A sustained reversal in the Fundamental Momentum research evidence.
  • New material public ownership disclosures.

Public filings · descriptive only

Elite Investor Activity

Reporting holders

5

New holders

3

Increasing

0

Reducing

1

Exiting

0

Coverage

Excellent

Positive disclosed activity · Report period 2022-12-31 · Public 12/19/2023

ManagerChangePortfolio weightRankDisclosed

Insufficient high-confidence manager coverage.

Objective stored changes

What changed

No qualifying changes are recorded for this company in the stored research and filing history.

Ownership timeline

No high-confidence public ownership events are available.

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.